Loxo Oncology (LOXO) Earning Somewhat Favorable Press Coverage, Report Finds

Headlines about Loxo Oncology (NASDAQ:LOXO) have been trending somewhat positive this week, according to Accern Sentiment Analysis. The research group identifies negative and positive news coverage by analyzing more than 20 million news and blog sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Loxo Oncology earned a media sentiment score of 0.14 on Accern’s scale. Accern also gave media coverage about the biopharmaceutical company an impact score of 46.1613239591033 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the company’s share price in the next several days.

These are some of the headlines that may have effected Accern Sentiment Analysis’s scoring:

How to Become a New Pot Stock Millionaire

Loxo Oncology stock opened at $133.45 on Friday. The stock has a market cap of $4,060.62, a PE ratio of -25.13 and a beta of 2.32. Loxo Oncology has a 1-year low of $42.11 and a 1-year high of $138.54.

Loxo Oncology (NASDAQ:LOXO) last posted its earnings results on Thursday, March 1st. The biopharmaceutical company reported ($0.69) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($1.22) by $0.53. The firm had revenue of $21.30 million for the quarter. research analysts predict that Loxo Oncology will post 0.3 EPS for the current year.

LOXO has been the topic of a number of recent research reports. Stifel Nicolaus reaffirmed a “buy” rating and set a $135.00 price objective on shares of Loxo Oncology in a research note on Friday, March 2nd. Morgan Stanley cut Loxo Oncology from an “overweight” rating to an “equal weight” rating and set a $103.00 price objective on the stock. in a research note on Wednesday, March 21st. They noted that the move was a valuation call. Cann initiated coverage on Loxo Oncology in a research note on Wednesday, February 21st. They set an “outperform” rating and a $132.00 price objective on the stock. BidaskClub raised Loxo Oncology from a “hold” rating to a “buy” rating in a research note on Tuesday, January 23rd. Finally, Zacks Investment Research raised Loxo Oncology from a “sell” rating to a “hold” rating in a research note on Tuesday, January 9th. Twelve investment analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the stock. The company has a consensus rating of “Buy” and a consensus target price of $131.89.

In other news, VP Jennifer Burstein sold 1,700 shares of the stock in a transaction dated Tuesday, March 13th. The shares were sold at an average price of $131.33, for a total transaction of $223,261.00. Following the completion of the sale, the vice president now directly owns 1,700 shares in the company, valued at $223,261. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, Director Avi Z. Naider sold 15,000 shares of the stock in a transaction dated Monday, January 22nd. The stock was sold at an average price of $100.00, for a total transaction of $1,500,000.00. Following the sale, the director now owns 141,118 shares of the company’s stock, valued at $14,111,800. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 54,564 shares of company stock valued at $6,005,345. 44.40% of the stock is currently owned by company insiders.

COPYRIGHT VIOLATION NOTICE: “Loxo Oncology (LOXO) Earning Somewhat Favorable Press Coverage, Report Finds” was originally posted by The Ledger Gazette and is the sole property of of The Ledger Gazette. If you are viewing this news story on another website, it was illegally stolen and reposted in violation of US & international trademark & copyright law. The correct version of this news story can be accessed at https://ledgergazette.com/2018/04/20/loxo-oncology-loxo-earning-somewhat-favorable-press-coverage-report-finds.html.

About Loxo Oncology

Loxo Oncology, Inc, a biopharmaceutical company, develops and sells medicines for patients with genetically defined cancers in the United States. Its lead product candidate comprises larotrectinib, an oral selective inhibitor of tropomyosin receptor kinase (TRK), which is in adult Phase 1 trial, a pediatric Phase 1/2 trial, and an adult/adolescent Phase 2 trial for the treatment of patients with tumor types, such as lung, head and neck, melanoma, colorectal, sarcoma, and breast cancer.

Insider Buying and Selling by Quarter for Loxo Oncology (NASDAQ:LOXO)

Receive News & Ratings for Loxo Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Loxo Oncology and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply